ArticleBMC infectious diseases2025
Emerging antibiotic resistance in bacterial bloodstream infections: a clinical study at the Holy Family Hospital, Nkawkaw, Ghana.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multidrug-resistant bacterial infections in a tertiary hospitals: culture positivity, pathogen spectrum, and antibiotic susceptibility.BMC microbiology · 2026Article
- Distribution and antimicrobial resistance profiles of common blood culture isolates in a maternal and child health specialty hospital, Shenzhen (January 2021-October 2025), China.Frontiers in microbiology · 2026Article
- Clinical outcomes and risk factors associated with bloodstream infections caused by multidrug-resistant Gram-negative bacteria in hospitalized patients: a prospective cohort study in Libya.Journal of medical microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacteraemia, a critical bloodstream infection caused by various bacterial pathogens, poses significant health challenges, particularly when compounded by antibiotic resistance. This current study determined the prevalence of bloodstream bacterial isolates and their antibiotic-resistant patterns at the Holy Family Hospital, Nkawkaw, Ghana, spanning a six-year period. METHODOLOGY: A hospital-based retrospective study was carried out to review records of bacterial isolates of bloodstream infections and their antibiotic-resistant pattern among patients who visited the Holy Family Hospital between 2018 and 2023. The data was collected into an Excel sheet version 2021, cleaned, and exported to the appropriate statistical software, SPSS v26 for statistical analysis. A P-value less than 0.05 was considered statistically significant for all analyses.
resultsOf 3,228 records in this study, the majority (66.0%) were found to be under 1 year of age, while 18.6% were aged 1-10 years. The prevalence of bacteraemia was 8.7% (95% CI: 7.8-9.7%). Klebsiella species was found to be the most prevalent at 30.2%, followed by S. aureus (26.0%). The highest levels of antibiotic resistance were detected against tetracycline (94.5%), penicillin (92.3%), and chloramphenicol (90.9%). Also, significant resistance was also found against vancomycin (88.3%), cefuroxime (86.5%), and cloxacillin (84.4%). Conversely, amikacin demonstrated the highest susceptibility rate (90.5%), followed by ciprofloxacin (75.0%).
conclusionThe study highlights the significant public health burden posed by bacteraemia and the growing challenge of antibiotic resistance. The prevalence of bacteraemia, particularly caused by Gram-negative organisms such as Klebsiella species and E. coli underscores the need for targeted interventions to improve infection control in healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.